IN2014DN08653A - - Google Patents
Info
- Publication number
- IN2014DN08653A IN2014DN08653A IN8653DEN2014A IN2014DN08653A IN 2014DN08653 A IN2014DN08653 A IN 2014DN08653A IN 8653DEN2014 A IN8653DEN2014 A IN 8653DEN2014A IN 2014DN08653 A IN2014DN08653 A IN 2014DN08653A
- Authority
- IN
- India
- Prior art keywords
- group
- hydrogen atom
- formula
- provides
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1) or the like. (In the formula R represents an aromatic hydrocarbon ring group or an aromatic heterocyclic group; R represents a hydrogen atom an alkyl group or a heterocycloalkyl group; R represents a hydrogen atom or an alkyl group; A represents a hydrogen atom or a hydroxyl group; L represents NHCO or OCH ; and X represents a nitrogen atom or =CH .)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012079859 | 2012-03-30 | ||
PCT/JP2013/059657 WO2013147216A1 (en) | 2012-03-30 | 2013-03-29 | (2-heteroarylamino)succinic acid derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN08653A true IN2014DN08653A (en) | 2015-05-22 |
Family
ID=49260457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN8653DEN2014 IN2014DN08653A (en) | 2012-03-30 | 2013-03-29 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9206168B2 (en) |
EP (1) | EP2832726B1 (en) |
JP (1) | JP6100755B2 (en) |
KR (1) | KR20140147825A (en) |
CN (1) | CN104334528A (en) |
CA (1) | CA2869135A1 (en) |
ES (1) | ES2649905T3 (en) |
HK (1) | HK1204622A1 (en) |
IN (1) | IN2014DN08653A (en) |
TW (1) | TW201400458A (en) |
WO (1) | WO2013147216A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9634549B2 (en) | 2013-10-31 | 2017-04-25 | General Electric Company | Dual phase magnetic material component and method of forming |
TWI773657B (en) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists |
WO2021003295A1 (en) * | 2019-07-02 | 2021-01-07 | Regeneron Pharmaceuticals, Inc. | Modulators of hsd17b13 and methods of use thereof |
CN111559982B (en) * | 2020-06-09 | 2023-04-07 | 天津市医药科学研究所 | 2- (2-substituted-4-hydroxypyrimidine-5-formamido) acetic acid compound and preparation method and application thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999040106A2 (en) * | 1998-02-09 | 1999-08-12 | University Of Southern California | Use of angiotensin analogues for promoting erythropoiesis |
IL163711A0 (en) * | 2002-03-08 | 2005-12-18 | Eisai Co Ltd | Macrocyclic compounds useful as pharmaceuticals |
CN101849943A (en) * | 2005-06-06 | 2010-10-06 | 菲布罗根公司 | Use the improved treatment for anemia of HIF alpha stabilizers |
NZ601730A (en) * | 2006-06-26 | 2014-04-30 | Akebia Therapeutics Inc | Prolyl hydroxylase inhibitors and methods of use |
ES2524883T3 (en) | 2008-03-18 | 2014-12-15 | Merck Sharp & Dohme Corp. | 4-Hydroxypyrimidine-5-substituted carboxamides |
AP2014007897A0 (en) * | 2008-04-01 | 2014-08-31 | Weir Minerals Australia Ltd | A lifter bar assembly for a crushing mill and method of installation |
TW200948788A (en) * | 2008-04-22 | 2009-12-01 | Daiichi Sankyo Co Ltd | 5-hydroxypyrimidine-4-carboxamide compounds |
WO2011002623A1 (en) | 2009-06-30 | 2011-01-06 | Merck Sharp & Dohme Corp. | Substituted 4-hydroxypyrimidine-5-carboxamides |
CN102802628A (en) | 2009-06-30 | 2012-11-28 | 默沙东公司 | Substituted 4-hydroxypyrimidine-5-carboxamides |
JP2011088840A (en) * | 2009-10-21 | 2011-05-06 | Daiichi Sankyo Co Ltd | Pharmaceutical composition comprising 5-hydroxypyrimidine-4-carboxamide compound |
PL2492266T3 (en) * | 2009-10-21 | 2016-01-29 | Daiichi Sankyo Co Ltd | 5-hydroxypyrimidine-4-carboxamide derivative |
JP2011105708A (en) * | 2009-10-21 | 2011-06-02 | Daiichi Sankyo Co Ltd | Pharmaceutical composition containing 5-hydroxypyrimidine-4-carboxamide compound |
TWI412114B (en) * | 2009-12-31 | 2013-10-11 | Advanced Semiconductor Eng | Semiconductor package and method for making the same |
WO2011132633A1 (en) * | 2010-04-19 | 2011-10-27 | 第一三共株式会社 | Substituted 5-hydroxypyrimidine-4-carboxamide compound |
-
2013
- 2013-03-29 IN IN8653DEN2014 patent/IN2014DN08653A/en unknown
- 2013-03-29 TW TW102111316A patent/TW201400458A/en unknown
- 2013-03-29 JP JP2014508120A patent/JP6100755B2/en not_active Expired - Fee Related
- 2013-03-29 EP EP13769439.4A patent/EP2832726B1/en not_active Not-in-force
- 2013-03-29 CA CA2869135A patent/CA2869135A1/en not_active Abandoned
- 2013-03-29 CN CN201380027575.6A patent/CN104334528A/en active Pending
- 2013-03-29 WO PCT/JP2013/059657 patent/WO2013147216A1/en active Application Filing
- 2013-03-29 KR KR1020147026676A patent/KR20140147825A/en not_active Application Discontinuation
- 2013-03-29 ES ES13769439.4T patent/ES2649905T3/en active Active
-
2014
- 2014-09-24 US US14/495,337 patent/US9206168B2/en not_active Expired - Fee Related
-
2015
- 2015-06-03 HK HK15105297.2A patent/HK1204622A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2832726B1 (en) | 2017-09-06 |
US9206168B2 (en) | 2015-12-08 |
US20150011574A1 (en) | 2015-01-08 |
EP2832726A4 (en) | 2015-12-02 |
HK1204622A1 (en) | 2015-11-27 |
CA2869135A1 (en) | 2013-10-03 |
CN104334528A (en) | 2015-02-04 |
EP2832726A1 (en) | 2015-02-04 |
WO2013147216A1 (en) | 2013-10-03 |
KR20140147825A (en) | 2014-12-30 |
ES2649905T3 (en) | 2018-01-16 |
JP6100755B2 (en) | 2017-03-22 |
TW201400458A (en) | 2014-01-01 |
JPWO2013147216A1 (en) | 2015-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN02574A (en) | ||
PH12015500263A1 (en) | New bicyclic derivatives | |
PH12014502697A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
TN2012000575A1 (en) | Compositions and methods for modulating the wnt signaling pathway | |
WO2014008458A3 (en) | N-substituted benzamides and methods of use thereof | |
IN2014MN02244A (en) | ||
MX2013006585A (en) | Indeno-fused ring compounds. | |
IN2014MN02211A (en) | ||
CR20140306A (en) | FLUORMETIL -5,6-DIHIDRO-4H- [1,3] OXAZINES | |
MX2014014531A (en) | Aminoquinazoline and pyridopyrimidine derivatives. | |
MY169267A (en) | New aryl-quinoline derivatives | |
MX346746B (en) | Indeno- fused ring compounds having photochromic properties. | |
MX2015001099A (en) | New bicyclicpyridine derivatives. | |
AU2013348091A8 (en) | Synthesis of spirocyclic isoxazoline derivatives | |
IN2014DN08653A (en) | ||
UA111950C2 (en) | HETEROCYCLIC COMPOUNDS FOR TREATMENT OR PREVENTION OF DISORDERS CAUSED BY REDUCED NERROTRANSMISSION OF SEROTONIN, NOREPINEPHIN OR DOPIN | |
MX369470B (en) | Means and method for treating solid tumours. | |
MX355415B (en) | Compositions and methods for modulating a kinase. | |
IN2015DN02588A (en) | ||
CO6660459A2 (en) | 4- (Methylaminophenoxy) pyridin-3-yl-benzamine derivatives to treat cancer | |
SE1100784A1 (en) | New phosphate compound | |
MX2013009388A (en) | New azaspirodecanone compounds as hsl inhibitors. | |
MX346980B (en) | New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds. | |
IN2015DN02514A (en) | ||
MX2015006828A (en) | Method for producing 4-haloalkyl -3-mercapto-substituted 2-hydroxy-benzoic acid derivatives. |